ARTICLE | Company News
KS Biomedix, MedPharm in antibody deal
May 29, 2001 7:00 AM UTC
KS Biomedix (LSE:KSB) will develop with MedPharm (London, U.K.) a solid suppository dosage form of its KSB304 antibody to treat ulcerative colitis. KSB304 targets the colonic epithelial protein, which...